Patents Examined by Bruce R. Campell
-
Patent number: 7244585Abstract: The present invention relates generally to the fields of biochemistry, molecular biology, and virology. More particularly, it relates to the identification of 259 nucleotides located at the 3? end of the GB virus B (GBV-B) genome. The invention involves nucleic acid constructs and compositions encoding GBV-B sequence, including the 3? end of the sequence, which has allowed an infectious GBV-B clone to be constructed. This construct, and chimeric versions of it, may be employed to study GBV-B and related hepatitis family members, such as hepatitis C virus. The invention thus includes methods of preparing GBV-B-containing sequences, constructs, and viruses, as well as methods of employing these compositions.Type: GrantFiled: June 5, 2000Date of Patent: July 17, 2007Assignee: The Board of Regents of The University of Texas SystemInventors: David V. Sangar, Stanley M. Lemon
-
Patent number: 7244435Abstract: The invention is for a DNA vaccine expressing the hemagglutinin (HA1) gene of equine-2 influenza virus. By engineering a stop codon within HA1, expression of HA1 is ensured. By encapsulation of the DNA vaccine in liposome and by intranasal inoculation, it is sufficient to elicit protective immunity at a significantly lower dosage compared to a DNA vaccine expressing the full length HA gene. Lower dosage reduces the risk of induction of anti-DNA antibodies. Intranasal inoculation directly to the respiratory epithelial cells reduces the risk of DNA integration. The inventive vaccine is advantageous over current inactivated or live attenuated vaccines, as updating of the vaccine requires only the replacement of the encoding sequence with the new virus.Type: GrantFiled: April 16, 2004Date of Patent: July 17, 2007Assignee: Board of Regents for Oklahoma State UniversityInventor: Alexander Lai
-
Patent number: 7244438Abstract: The invention relates to the use of a polycationic compound for the preparation of a medicament with retarded in vivo release.Type: GrantFiled: January 7, 2002Date of Patent: July 17, 2007Assignee: Intercell AGInventors: Karen Lingnau, Frank Mattner, Walter Schmidt, Michael Buschle
-
Patent number: 7244715Abstract: Compositions and methods for enhancing the effect of vaccines in animals, such as domestic, sport, or pet species, and humans are disclosed. More particularly, vaccine compositions comprising ribavirin and an antigen, preferably an antigen that has an epitope present in Hepatitis C virus (HCV), are disclosed for use in treating and preventing disease, preferably HCV infection.Type: GrantFiled: April 26, 2006Date of Patent: July 17, 2007Assignee: Tripep ABInventors: Matti Sällberg, Catharina Hultgren
-
Patent number: 7244422Abstract: The present invention relates to compositions and methods for enhancing the effect of vaccines in animals, such as domestic, sport, or pet species, and humans. More particularly, the use of Ribavirin as an adjuvant to a vaccine protocol and compositions having Ribavirin and an antigen are described.Type: GrantFiled: April 24, 2006Date of Patent: July 17, 2007Assignee: Tripep ABInventors: Matti Sällberg, Catharina Hultgren
-
Patent number: 7244432Abstract: A VP2 protein isolated from a variant Georgia strain of Infectious Bursal Disease Virus (IBDV) and method of generating such VP2 protein and variant strain for use to reduce or prevent infection in poultry by IBDV.Type: GrantFiled: June 29, 2005Date of Patent: July 17, 2007Assignee: University of Maryland Biotechnology InstituteInventor: Vikram Vakharia
-
Patent number: 7244558Abstract: The present invention concerns cDNAs for making attentuated, infectious Newcastle disease virus (NDV). Another aspect of the invention relates to methods of making the cDNAs. Another aspect of the invention is a vector containing the cDNA optionally linked to an operable promoter. Within the scope of the invention are vaccines comprising the attenuated, infectious NDV. Also disclosed are methods of making the vaccines and methods of using the vaccines to prevent or treat Newcastle disease in an avian host. The present invention also concerns the nucleotide sequences of the entire genome of NDV, the leading region, the trailing region, and the NP region, as well as proteins encoded by these nucleotide sequences.Type: GrantFiled: May 5, 2000Date of Patent: July 17, 2007Assignees: University of Maryland, The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Siba K. Samal, Peter L. Collins
-
Patent number: 7244814Abstract: Variants of the HIV-1 Tat protein exhibiting higher transcriptional activation and stronger P-TEFb binding than wild-type Tat are provided. In addition variants that can inhibit transcription activation by wild-type Tat are provided. Nucleic acid sequences encoding these variants, vectors and host cells for expression of these variants, and antibodies raised against these variants are also provided. In addition, methods for use of these variants and compositions containing these variants as research tools, as diagnostic tools and in the treatment of viral infections are provided.Type: GrantFiled: February 21, 2003Date of Patent: July 17, 2007Assignee: University of Medicine & Dentistry of New JerseyInventors: Michael B. Mathews, Tsafi Pe'ery, Syed Reza
-
Patent number: 7241447Abstract: The invention provides an isolated and purified DNA molecule comprising at least one DNA segment, a biologically active subunit or variant thereof, of a circular intermediate of adeno-associated virus, which DNA segment confers increased episomal stability, persistence or abundance of the isolated DNA molecule in a host cell. The invention also provides a composition comprising at least two adeno-associated virus vectors.Type: GrantFiled: October 6, 2000Date of Patent: July 10, 2007Assignee: University of Iowa Research FoundationInventors: John F. Engelhardt, Dongsheng Duan, Ziying Yan
-
Patent number: 7241440Abstract: Compositions and methods for enhancing the effect of vaccines in animals, such as domestic, sport, or pet species, and humans are disclosed. More particularly, vaccine compositions comprising ribavirin and an antigen, preferably an antigen that has an epitope present in Hepatitis C virus (HCV), are disclosed for use in treating and preventing disease, preferably HCV infection.Type: GrantFiled: April 2, 2004Date of Patent: July 10, 2007Assignee: Tripep ABInventors: Matti Sällberg, Catharina Hultgren
-
Patent number: 7241582Abstract: This invention provides kits, devices, and methods for the detection of antibodies that recognize one or more proteins and/or antigens from porcine reproductive and respiratory syndrome virus (PRRSV). The antibodies may be in a biological fluid of a PRRSV infected or at risk subject. The invention may be advantageously applied to both the diagnosis and prevention of PRRSV infection.Type: GrantFiled: July 5, 2005Date of Patent: July 10, 2007Assignee: MJ Biologics, Inc.Inventors: Han-Soo Joo, Eugenio P. Mende
-
Patent number: 7241445Abstract: Disclosed is a hybridoma cell line which produces human antibodies capable of binding to the hepatitis C virus (HCV) E2 glycoprotein and capable of neutralizing HCV infection in vivo in an animal model, as well as antibodies produced by the cell line. Also disclosed are various uses of said antibodies in the prevention and treatment of HCV infection. Peripheral blood lymphocytes obtained from human donors having a high titer of anti HCV E2 antibodies are transformed in vitro by Epstein-Barr virus and then fused with heteromyeloma cells to generate hybridomas secreting human antibodies having a high affinity and specificity to HCV E2 glycoprotein.Type: GrantFiled: July 25, 2001Date of Patent: July 10, 2007Assignee: DRK-Blutspendedienst Baden-WurttembergInventors: Bernhard Kubanek, Marcia Da Silva Cardoso, Karl Sifmoneit, Shlomo Dagan, Rachel Eren
-
Patent number: 7238672Abstract: The present invention provides chimeric nucleic acids, preferably contained on an expression vector, that encode chimeric immunogenic polypeptides. The nucleic acids encode at least site III of a lyssavirus glycoprotein, which has been found to improve the immunogenicity of lyssavirus epitopes for protection from rabies. The chimeric nucleic acids and proteins can also contain antigenic determinants for epitopes other than those of lyssavirus. Thus, the invention provides chimeric nucleic acids and polypeptides that elicit a strong immune response to multiple antigens. Use of the methods of the present invention permits DNA vaccination without the need to supply multiple antigens on separate DNA molecules.Type: GrantFiled: April 17, 2000Date of Patent: July 3, 2007Assignee: Institut PasteurInventors: Yves Jacob, Pierre Perrin, Noël Tordo, Chokri Bahloul
-
Patent number: 7238526Abstract: Methods for efficient production of recombinant AAV employ a host cell which comprising AAV rep and cap genes stably integrated within the cell's chromosomes, wherein the AAV rep and cap genes are each operatively linked to regulatory sequences capable of directing the expression of the rep and cap gene products upon infection of the cell with a helper virus, a helper gene, and a helper gene product. A method for producing recombinant adeno-associated virus (rAAV) involves infecting such a host cell with a helper virus, gene or gene product and infecting the infected host cell with a recombinant hybrid virus or plasmid vector containing adenovirus cis-elements necessary for replication and virion encapsidation, AAV sequences comprising the 5? and 3? ITRs of an AAV, and a selected gene operatively linked to regulatory sequences directing its expression, which is flanked by the above-mentioned AAV sequences.Type: GrantFiled: September 11, 2002Date of Patent: July 3, 2007Assignee: The Trustees of the University of PennsylvaniaInventors: James M. Wilson, Guangping Gao
-
Patent number: 7238349Abstract: The invention provides a monovalent influenza vaccine comprising a low dose of egg-derived influenza virus antigen from an influenza virus strain that is associated with a pandemic outbreak or has the potential to be associated with a pandemic outbreak, in combination with an aluminium adjuvant. The invention also provides vaccine kits comprising a combination of a parenteral and a mucosal influenza vaccine, wherein the combined dose of antigen is no more than the conventional antigen dose. Also provided are methods for preparing the vaccines.Type: GrantFiled: September 27, 2000Date of Patent: July 3, 2007Assignees: SmithKline Beecham Biologicals, s.a., Saechsisches Serumwerk DresdenInventors: Erik D'Hondt, Norbert Hehme
-
Patent number: 7238777Abstract: The object of the present invention is to provide an agent for specific adsorption of type 5 adenoviral vector to undifferentiated blood cells which enables infection with a viral concentration that does not impart toxicity to undifferentiated blood cells, without requiring the construction of a new viral genome, or special modification of viral particles such as biotination, etc. The above objective has been achieved by providing a polypeptide which has affinity for both adenovirus and undifferentiated blood cells. Use of the polypeptide of the present invention enables improved efficiency of adenoviral vector-mediated gene transfer of any gene to undifferentiated blood cells, and there is provided a method of introducing any gene for which transient expression in these cells is desired. In particular, the method is useful for intracellular DNA recombination by transiently expressing site-specific recombinase, and for induction into any cells of different lines by transient expression of master genes.Type: GrantFiled: October 16, 2002Date of Patent: July 3, 2007Assignee: Asahi Kasei Kabushiki KaishaInventors: Akira Itoh, Yutaka Hanazono, Takashi Okada, Keiya Ozawa
-
Patent number: 7238356Abstract: The current invention relates to HCV envelope proteins or parts thereof which are the product of expression in eukaryotic cells. More particularly said HCV envelope proteins are characterized in that on average up to 80% of their N-glycosylation sites are core-glycosylated. Of these N-glycosylated sites more than 70% are glycosylated with an oligomannose having a structure defined by Man(8 to 10)-GlcNAc(2). Furthermore, the ratio of the oligomannose with structure Man(7)-GlcNAc(2) over the oligomannose with structure Man(8)-GlcNAc(2) is less than or equal to 0.45. Less than 10% of the oligomannoses is terminated with an ?1,3 linked mannose. The HCV envelope proteins of the invention are particularly suited for diagnostic, prophylactic and therapeutic purposes. A suitable eukaryotic cell for production of the HCV envelope proteins of the invention is a Hansenula cell.Type: GrantFiled: April 24, 2002Date of Patent: July 3, 2007Assignee: Innogenetics N.V.Inventors: Fons Bosman, Erik Depla, Geert Deschamps, Erwin Sablon, Manfred Suckow, Isabelle Samson, Gert Verheyden
-
Patent number: 7235392Abstract: Cell preparations comprising a plurality of apoptotic EBV-transformed B lymphocytes and methods of producing cell preparations comprising a plurality of apoptotic EBV-transformed B lymphocytes. The methods comprise transforming B lymphocytes with EBV, incubating the transformed B lymphocytes with a flavin N-oxide photosensitizer, adding a non-toxic antioxidant, and exposing the lymphocytes to an activator, such as photoradiation of an appropriate wavelength to activate the photosensitizer. Also provided are methods of using the apoptotic EBV-transformed B lymphocyte cell preparations to elicit production of EBV-specific T cells in human patients. Finally, methods of treating organ transplant patients, specifically children, comprising administering an effective amount of the apoptotic EBV-transformed B-lymphocyte cell preparation to the patient prior to transplantation are provided.Type: GrantFiled: May 12, 2003Date of Patent: June 26, 2007Assignee: The Ohio State University Research FoundationInventor: Matthew S. Platz
-
Patent number: 7235235Abstract: The present invention provides a helper cell for expressing an infectious, replication defective, alphavirus particle in an alphavirus-permissive cell. The helper cell includes (a) a first helper RNA encoding (i) at least one alphavirus structural protein, and (ii) not encoding at least one alphavirus structural protein; and (b) a second helper RNA separate from the first helper RNA, the second helper RNA (i) not encoding the alphavirus structural protein encoded by the first helper RNA, and (ii) encoding the at least alphavirus one structural protein not encoded by the first helper RNA, such that all of the alphavirus structural proteins assemble together into alphavirus particles in the cell. Preferably, the helper cell also includes a replicon RNA encoding an alphavirus packaging sequence and an inserted heterogeneous RNA.Type: GrantFiled: March 13, 2003Date of Patent: June 26, 2007Assignee: University of North Carolina at Chapel HillInventors: Robert E. Johnston, Nancy L. Davis, Jonathan F. Smith, Peter Pushko, Michael Parker, George Ludwig
-
Patent number: 7235245Abstract: The present invention provides chimeric nucleic acids, preferably contained on an expression vector, that encode chimeric immunogenic polypeptides. The nucleic acids encode at least site III of a lyssavirus glycoprotein, which has been found to improve the immunogenicity of lyssavirus epitopes for protection from rabies. The chimeric nucleic acids and proteins can also contain antigenic determinants for epitopes other than those of lyssavirus. Thus, the invention provides chimeric nucleic acids and polypeptides that elicit a strong immune response to multiple antigens. Use of the methods of the present invention permits DNA vaccination without the need to supply multiple antigens on separate DNA molecules.Type: GrantFiled: June 30, 2003Date of Patent: June 26, 2007Assignee: Institut PasteurInventors: Yves Jacob, Pierre Perrin, Noël Tordo, Chokri Bahloul